Ozagrel

Ozagrel is a thromboxane A2 (TXA2) synthase inhibitor. It is used in the treatment of cerebral infarction and its sequelae. Ozagrel works by inhibiting the synthesis of thromboxane, which is a substance that causes blood clot formation and blood vessel constriction.

Mechanism of Action

Ozagrel inhibits the enzyme thromboxane A2 synthase, which is responsible for the production of thromboxane. Thromboxane is a potent vasoconstrictor and a potent inducer of platelet aggregation. By inhibiting the production of thromboxane, Ozagrel reduces the risk of blood clot formation and blood vessel constriction, which can lead to cerebral infarction.

Uses

Ozagrel is used in the treatment of cerebral infarction and its sequelae. Cerebral infarction is a type of stroke caused by a blockage in the blood vessels supplying blood to the brain. The sequelae of cerebral infarction can include paralysis, speech impairment, and cognitive impairment.

Side Effects

The most common side effects of Ozagrel include nausea, vomiting, abdominal pain, and diarrhea. Less common side effects can include dizziness, headache, rash, and itching.

Contraindications

Ozagrel is contraindicated in patients with a history of hypersensitivity to Ozagrel or any of its components. It is also contraindicated in patients with active gastrointestinal bleeding or a history of asthma.

See Also

• Thromboxane A2
• Cerebral Infarction
• Stroke

Ozagrel Resources
Latest articles Most recent articles Ongoing trials	Wikipedia